Helus Pharma Inc. carries no debt; cash flow comfortably covers obligations.

Helus Pharma Inc.'s free cash flow has decreased 29.55% from $-103.27M last year to $-133.79M, signaling decreasing performance

Helus Pharma Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Helus Pharma Inc. has insufficient data to evaluate this check.

Helus Pharma Inc. has a net cash position, so leverage is healthy.

Helus Pharma Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Helus Pharma Inc.'s profit margin was -23.96K% last year and is 0.00% this year, signaling increasing performance

Helus Pharma Inc.'s short-term assets of $185.11M exceed its short-term liabilities of $19.44M

Helus Pharma Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Helus Pharma Inc.'s return on equity of -74.47%, is lower than 15.00%, indicating bad performance

Helus Pharma Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Helus Pharma Inc. has insufficient public price history to evaluate earnings stability.

Helus Pharma Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Helus Pharma Inc. has negative free cash flow, indicating cash burn

Helus Pharma Inc.'s yearly earnings has decreased 29.98% since last year from $-113.14M to $-147.05M, signaling decreasing performance

Helus Pharma Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -70.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Helus Pharma Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Helus Pharma Inc. has insufficient public price history to evaluate revenue consistency.

Helus Pharma Inc. has insufficient public price history to evaluate ROE consistency.

Helus Pharma Inc. has insufficient data to evaluate this check.

Helus Pharma Inc. has insufficient data to evaluate this check.

Helus Pharma Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Helus Pharma Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Helus Pharma Inc. has insufficient data to evaluate this check.

Helus Pharma Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Helus Pharma Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Helus Pharma Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue